VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Stock Comparison

ChemoMetec A/S vs Pfizer Inc.

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

ChemoMetec A/S

CHEMM · Nasdaq Copenhagen A/S

Market cap (USD)
Gross margin (TTM)
Operating margin (TTM)
Net margin (TTM)
SectorHealthcare
Industry
CountryDK
Data as of2026-04-24
Moat score
67/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into ChemoMetec A/S's moat claims, evidence, and risks.

View CHEMM analysis

Pfizer Inc.

PFE · New York Stock Exchange

Market cap (USD)$151.6B
Gross margin (TTM)70.3%
Operating margin (TTM)24.7%
Net margin (TTM)12.4%
SectorHealthcare
IndustryDrug Manufacturers - General
CountryUS
Data as of2025-12-29
Moat score
58/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Pfizer Inc.'s moat claims, evidence, and risks.

View PFE analysis

Comparison highlights

  • Moat score gap: ChemoMetec A/S leads (67 / 100 vs 58 / 100 for Pfizer Inc.).
  • Segment focus: ChemoMetec A/S has 2 segments (94.8% in Life science research, cell and gene therapy, and bioprocessing); Pfizer Inc. has 5 segments (47.4% in Primary Care).
  • Moat breadth: ChemoMetec A/S has 4 moat types across 2 domains; Pfizer Inc. has 8 across 3.

Primary market context

ChemoMetec A/S

Life science research, cell and gene therapy, and bioprocessing

Market

Global cell counting and analysis instruments for LCB workflows

Geography

Global, skewed to USA/Canada and Europe

Customer

Pharmaceutical, biotech, cell and gene therapy, bioprocessing, and research labs

Role

OEM instrument, consumables, software, and service provider

Revenue share

94.8%

Pfizer Inc.

Primary Care

Market

Branded primary care medicines and vaccines (incl. cardiovascular, migraine, pneumococcal/RSV/COVID-19)

Geography

Global

Customer

Healthcare providers, payers/PBMs, pharmacies/wholesalers, and government procurement

Role

Innovator biopharma (R&D + manufacturing + commercialization)

Revenue share

47.4%

Side-by-side metrics

ChemoMetec A/S
Pfizer Inc.
Ticker / Exchange
CHEMM - Nasdaq Copenhagen A/S
PFE - New York Stock Exchange
Market cap (USD)
n/a
$151.6B
Gross margin (TTM)
n/a
70.3%
Operating margin (TTM)
n/a
24.7%
Net margin (TTM)
n/a
12.4%
Sector
Healthcare
Healthcare
Industry
n/a
Drug Manufacturers - General
HQ country
DK
US
Primary segment
Life science research, cell and gene therapy, and bioprocessing
Primary Care
Market structure
Oligopoly
Oligopoly
Market share
15%-25% (estimated)
n/a
HHI estimate
n/a
n/a
Pricing power
Moderate
Moderate
Moat score
67 / 100
58 / 100
Moat domains
Demand, Network
Legal, Demand, Supply
Last update
2026-04-24
2025-12-29

Moat coverage

Shared moat types

No overlap yet.

ChemoMetec A/S strengths

Installed Base ConsumablesDesign In QualificationInteroperability HubBrand Trust

Pfizer Inc. strengths

IP Choke PointProcurement InertiaGovernment Contracting RelationshipsCapex Knowhow ScaleCompliance AdvantageLong Term ContractsOperational ExcellenceEmbedded R&D partnership platform

Segment mix

ChemoMetec A/S segments

Full profile >

Life science research, cell and gene therapy, and bioprocessing

Oligopoly

94.8%

Production control and quality control of animal semen, beer and milk

Quasi-Monopoly

5.2%

Pfizer Inc. segments

Full profile >

Primary Care

Oligopoly

47.4%

Specialty Care

Oligopoly

26.2%

Oncology

Competitive

24.5%

Pfizer CentreOne

Competitive

1.8%

Pfizer Ignite

Competitive

0.1%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.